Clinical Trial Update: Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update notes that luspatercept is being evaluated in Phase 2/Phase 3 studies to prevent poor erythroid engraftment in patients with hematologic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Myelofibrosis

Drugs mentioned

• Luspatercept (Reblozyl) (luspatercept)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Luspatercept, Poor Erythroid Engraftment | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING